AU2025283494A1 — Implants with controlled drug delivery features and methods of using same
Assigned to Glaukos Corp · Expires 2026-01-15 · 0y expired
What this patent protects
A drug delivery ocular implant comprising: an outer shell comprising a sidewall defining an interior lumen; a drug positioned within the interior lumen; a cap at least partially closing an opening of the outer shell, the cap comprising an aperture defining a region of drug releas…
USPTO Abstract
A drug delivery ocular implant comprising: an outer shell comprising a sidewall defining an interior lumen; a drug positioned within the interior lumen; a cap at least partially closing an opening of the outer shell, the cap comprising an aperture defining a region of drug release; and a membrane comprising elastic properties, the membrane being permeable or semi- permeable to the drug, the elastic properties configured to retain the position of the membrane, thereby limiting fluid communication between the interior lumen and an outer environment to that occurring through the membrane.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.